Small Cell Lung Cancer: Advances in Diagnosis and Management.

Autor:	Chauhan AF; Division of Medical Oncology, Georgetown University, Washington, District of Columbia, Washington, DC., Liu SV; Division of Medical Oncology, Georgetown University, Washington, District of Columbia, Washington, DC.
Jazyk:	angličtina
Zdroj:	Seminars in respiratory and critical care medicine [Semin Respir Crit Care Med] 2020 Jun; Vol. 41 (3), pp. 435-446. Date of Electronic Publication: 2020 May 25.
DOI:	10.1055/s-0039-1700566
Abstrakt:	Small cell lung cancer (SCLC) is an aggressive subtype of lung cancer characterized by rapid growth and early spread. It is a highly lethal disease that typically is diagnosed at a late stage. Surgery plays a very small role in this cancer, and management typically involves chemotherapy, delivered with thoracic radiation in early-stage disease. Platinum-based chemotherapy is initially very effective, inducing rapid and often deep responses. These responses, though, are transient, and upon relapse, SCLC is highly refractory to therapy. Immunotherapy has shown promise in delivering meaningful, durable responses and the addition of immunotherapy to first-line chemotherapy has led to the first improvements in survival in decades. Still, the disease remains difficult to manage. Incorporating radiation therapy at specific points in patient management may improve disease control. The development of predictive biomarkers and novel targeted therapies will hopefully improve options for patients in the near future. This review focuses on the current standards of care and future directions. Competing Interests: Dr. Liu reports grants from Alkermes, grants and personal fees from AstraZeneca, grants from Bayer, personal fees from Boehringer-Ingelheim, grants and personal fees from Bristol-Myers Squibb, personal fees from Catalyst, from Celgene, grants from Corvus, personal fees from G1 Therapeutics, grants and personal fees from Genentech, personal fees from Guardant Health, personal fees from Janssen, grants and personal fees from Lilly, personal fees from LOXO, grants from Lycera, grants and personal fees from Merck/MSD, grants from Merus, grants from Molecular Partners, grants and personal fees from Pfizer, personal fees from PharmaMar, grants from Rain Therapeutics, grants from RAPT, personal fees from Regeneron, grants from Spectrum, personal fees from Takeda, grants from Turning Point Therapeutics, outside the submitted work. (Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu